RATE OF MALIGNANCIES AND INFECTIONS IN A LARGE SINGLE CENTER COHORT OF IBD PATIENTS TREATED WITH THIOPURINES AND ANTI-TNF-ANTIBODIES

(1) IBD CENTER

(2) Montefiore Institute



This item was part of the Safety of anti-TNFs and immunomodulators in IBD session at UEG Week Stockholm 2011

This item can be cited as: Gut 2011; 60 (Suppl 3) A35